ERVW-1: A Drug Target / Disease Biomarker (G30816)

Target Name: ERVW-1

NCBI ID: G30816

ERVW-1

Other Name(s): enverin | HERV-W envelope protein | SYCY1_HUMAN | Syncytin-1 | Envelope protein | human endogenous retrovirus W envC7-1 envelope protein | envelope polyprotein gPr73 | Envelope polyprotein gPr73 | SU | endogenous retrovirus group W, member 1 | Syncytin A | Envelope glycoprotein | ENV | HERV-W-ENV | Syncytin | HERVWENV | endogenous retrovirus group W member 1, envelope | HERV-7q | Endogenous retrovirus group W member 1, envelope, transcript variant 1 | Surface protein | TM | HERV7Q | gp24 | HERV-7q Envelope protein | envelope glycoprotein | ERVWE1 | HERV-tryptophan envelope protein | ENVW | Human endogenous retrovirus W envC7-1 envelope protein | Env-W | HERV-7q envelope protein | HERVW | endogenous retroviral family W, env(C7), member 1 | Endogenous retrovirus group W member 1 | HERV-W{7q21.1} provirus ancestral Env polyprotein | ERVW-1 variant 1 | Transmembrane protein | HERV-W Env glycoprotein | Enverin | gp50 | HERV-W_7q21.2 provirus ancestral Env polyprotein

ERVW-1: A Drug Target / Disease Biomarker

ERVW-1 (endogenous retrovirus-1) is a member of the endogenous retrovirus family, which includes viruses that integrate into the host's DNA and replicate when the host is infected with an retrovirus. ERVW-1 is found in most humans and is responsible for a variety of physiological processes in the body, including immune surveillance and gene expression.

Recent studies have suggested that ERVW-1 may have potential as a drug target or biomarker for a variety of diseases. One potential mechanism by which ERVW-1 could be targeted is its role in the development of cancer. ERVW-1 has been shown to promote the growth and progression of cancer cells, and it has also been found to be expressed in the tissues of many cancer patients.

Another potential mechanism by which ERVW-1 could be targeted is its role in the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. ERVW-1 has been shown to cause neurotoxicity in the brain and has been linked to the development of these diseases.

In addition to its potential as a drug target or biomarker, ERVW-1 has also been shown to have a variety of potential therapeutic applications. For example, it has been shown to be effective in treating herpes simplex virus (HSV) infection, a common cause of painful sores on the skin and mucous membranes.

ERVW-1 has also been shown to be effective in treating human immunodeficiency virus (HIV) infection, a condition that has a significant impact on immune function and can lead to a variety of serious health complications.

In addition to its potential therapeutic applications, ERVW-1 also has a number of potential scientific research applications. For example, it has been used as a model for studying the replication and immune response of viruses, which has led to a greater understanding of the mechanisms underlying retroviral infection.

Overall, ERVW-1 is a fascinating virus that has a variety of potential applications in medical research and treatment. While further research is needed to fully understand its mechanisms of action and its potential as a drug target or biomarker, its potential therapeutic applications are already a promising area of research.

Protein Name: Endogenous Retrovirus Group W Member 1, Envelope

Functions: This endogenous retroviral envelope protein has retained its original fusogenic properties and participates in trophoblast fusion and the formation of a syncytium during placenta morphogenesis. May induce fusion through binding of SLC1A4 and SLC1A5 (PubMed:10708449, PubMed:12050356, PubMed:23492904)

The "ERVW-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ERVW-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets